Celularity, Inc. (NASDAQ:CELU) Short Interest Update

Celularity, Inc. (NASDAQ:CELU) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totaling 1,897,722 shares, an increase of 370.2% from the August 15th total of 403,568 shares. Based on an average daily volume of 21,797,628 shares, the short-interest ratio is currently 0.1 days. Approximately 7.9% of the shares of the stock are sold short.

Hedge Funds Weigh In On Celularity

Several institutional investors and hedge funds have recently added to or reduced their stakes in CELU. C V Starr & Co. Inc. acquired a new stake in shares of Celularity during the second quarter worth $1,582,000. Geode Capital Management LLC increased its stake in shares of Celularity by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock valued at $178,000 after acquiring an additional 20,876 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Celularity by 35.3% in the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after acquiring an additional 176,518 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Celularity during the 4th quarter valued at $46,000. Finally, Bank of America Corp DE lifted its position in shares of Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after acquiring an additional 35,023 shares during the period. Institutional investors own 19.02% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Celularity currently has an average rating of “Sell”.

Celularity Stock Down 1.7%

Shares of CELU stock traded down $0.03 on Friday, reaching $1.41. The company had a trading volume of 96,695 shares, compared to its average volume of 12,236,725. The business’s 50-day moving average is $0.97 and its 200 day moving average is $1.01. Celularity has a one year low of $0.56 and a one year high of $2.55. The stock has a market capitalization of $40.82 million, a PE ratio of -0.42 and a beta of 0.79.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.